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ABSTRACT: The reactivation of nerve agent-inhibited acetylcholinesterase (AChE) by oxime is the most
important step in the treatment of nerve agent poisoning. Since the evaluation of nerve agent antidotes
cannot be conducted in humans, results from animal experiments are extrapolated to humans. Guinea pig
is one of the animal models that is frequently used for conducting nerve agent antidote evaluations. Several
investigations have demonstrated that the efficacy of an oxime primarily depends on its ability to reactivate
nerve agent-inhibited AChE. If the in Vitro oxime reactivation of nerve agent-inhibited animal AChE is
similar to that of human AChE, it is likely that the results of an in ViVo animal study will reliably extrapolate
to humans. Therefore, the goal of this study was to compare the reactivation of guinea pig and human
AChEs inhibited by six different G and V type nerve agents. Reactivation kinetic studies with five mono-
and bis-pyridinium oximes showed that oxime reactivation of nerve agent-inhibited human AChE in most
cases was faster than guinea pig AChE. The most significant enhancement was observed in the reactivation
of human AChE inhibited by nerve agents containing bulky side chains GF, GD, and VR, by H-series
oximes HLo-7, HI-6, and ICD-585. In these cases, species-related differences observed between the two
AChEs, based on the second-order reactivation rate constants, were 90- to over 400-fold. On the other
hand, less than 3-fold differences were observed in the rates of aging of nerve agent-inhibited guinea pig
and human AChEs. These results suggest that the remarkable species-related differences observed in the
reactivation of nerve agent-inhibited guinea pig and human AChEs were not due to differences in the
rates of aging. These results also suggest that guinea pig may not be an appropriate animal model for the
in ViVo evaluation of oxime therapy.
Organophosphorus (OP1) nerve agents, such as the G-type
agents sarin (GB), soman (GD), cyclosarin (GF), and tabun
(GA), and V-type agents VX and VR, are a group of highly
toxic compounds, which can be utilized as chemical warfare
agents. Despite great efforts to prohibit the use of chemical
warfare agents by many countries, the threat of these agents
is still enormous, as evidenced by the Iran-Iraq war and
the Tokyo subway incident in Japan (1, 2). The primary target
of nerve agents is acetylcholinesterase (AChE; EC 3.1.1.7),
the enzyme that terminates neurotransmission at the post-
synapses of cholinergic neurons by catalyzing the hydrolysis
of the neurotransmitter acetylcholine. OP nerve agents
irreversibly inhibit AChE by forming a covalent adduct with
the hydroxyl group of the active site serine, resulting in
successive accumulation of acetylcholine, overstimulation of
cholinergic receptors, and finally paralysis of neuromuscular
functions and death of the victim (3).
The standard treatment for nerve agent poisoning uses a
muscarinic antagonist atropine, an oxime reactivator, and an
anticonvulsant diazepam, if needed (4). As depicted in
Scheme 1, an oxime is used to restore the activity of nerve
agent-inhibited AChE, a process called reactivation. This is
an important step in the successful treatment of nerve agent
poisoning since it is the only practical means for recovering
the activity of synaptic AChE inhibited by nerve agents. For
this reason, different oxime compounds are used by various
countries for the treatment of nerve agent poisoning. For
example, the bis-pyridinium oxime obidoxime is used in
European countries, while the mono-pyridinium oxime
pralidoxime (2-PAM) is used in the United States. The dry
powder form of HI-6 is used in auto-injectors in Canada,
the only oxime that is a potent reactivator of AChE inhibited
by GD and GF (5-7). However, HI-6 does not reactivate
AChE inhibited by GA (8-10) and is also a poor reactivator
of AChE inhibited by OP pesticides such as paraoxon (11,
12). For this reason, new oximes with broad-spectrum
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1 Abbreviations: AChE, acetylcholinesterase; GP AChE, guinea pig
erythrocyte acetylcholinesterase; rHu AChE, recombinant human
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phorus compounds; DEPQ, 7-(O,O-diethyl-phosphinyloxy)-1-methyl-
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(cyclosarin), O-cyclohexyl methylphosphonofluoridate; GA (tabun),
O-ethyl N,N-dimethylphosphoramidocyanate; VX, O-ethyl S-2-N,N-
diisopropylaminoethyl methylphosphonothiolate; VR, O-isobutyl S-2-
N,N-diethylaminoethyl methylphosphonothiolate; 2-PAM, 2-[hydrox-
yimino methyl]-1-methyl-pyridinium chloride; MMB4, 1,1′-trimethylene
bis(4-hydroxyimino methyl) pyridinium dichloride; HI-6, 1-[[[4-(ami-
nocarbonyl)pyridinio]methoxy]methyl]-2-[(hydroxyimino)methyl]-py-
ridinium dimethanesulfonate; HLo-7, 1-[[[4-(aminocarbonyl)pyridinio]-
methoxy]methyl]-2,4-bis-[(hydroxylimino)methyl] pyridinium dimethane-
sulfonate; ICD-585, 1-(2-hydroxyiminomethyl-1-pyridinium)-1′-(4-car-
boxy-aminopyridinium)-trimethylene hydrochloride; POX, phosphoryl
oxime; PIPLC, phosphatidylinositol-specific phospholipase C; BSA,
bovine serum albumin.
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activity in reactivating AChE inhibited by all nerve agents
are being actively sought as the next generation of antidotes
(6, 13).
Since efficacy evaluations of oximes cannot be conducted
in humans for ethical reasons, various animal models are
used to evaluate nerve agent antidotes, and results from
animal studies are extrapolated to humans. Due to the
complexity of the in ViVo system, the accuracy for extrapo-
lating results from animal studies to humans depends on
many factors, such as the distribution and metabolism of the
nerve agent and antidote, the sensitivity of the specific OP
nerve agent for the inhibition of animal and human AChEs,
and differences in the endogenous levels of nerve agent
scavenging enzymes, such as butyrylcholinesterase (14), OP
hydrolases (15), and carboxylesterase (16). To allow a
reasonable animal-to-human extrapolation of experimental
results, in Vitro comparisons of reactivation of nerve agent-
inhibited animal and human AChEs by oxime are conducted.
The advantages of this method are several-fold. First, kinetic
measurements of oxime reactivation yield multiple param-
eters, such as oxime affinity and oxime reactivity, that can
be used to design better oximes. Second, the interaction of
an oxime with the pharmacological target (i.e., AChE) is
not influenced by its pharmacokinetics and can be more
precisely analyzed. Third, AChE reactivation is a more
sensitive measure of oxime effectiveness than in ViVo survival
because the background signal (i.e., AChE activity) for
reactivation is much lower than the background signal (i.e.,
agent LD50) for in ViVo efficacy in animals. Although this
simplified in Vitro evaluation does not consider other factors
that affect in ViVo antidotal efficacy, several investigations
have demonstrated that there is a reasonable correlation
between in Vitro and in ViVo data, and the efficacy of an
oxime primarily depends on its ability to reactivate nerve
agent-inhibited AChE (17-19). If the in Vitro oxime
reactivation of nerve agent-inhibited animal AChE is similar
to that of human AChE, it is likely that the results of in
ViVo animal study will reliably extrapolate to humans.
The guinea pig is a frequently used animal model for the
evaluation of nerve agent antidotes (7, 16, 20-21). However,
there is only one in Vitro study reported to date that
investigated the oxime reactivation of guinea pig (GP) AChE
(22). Using erythrocyte ghosts as the source of enzyme,
significant species-related differences were observed between
the oxime reactivation of GB-, GF- and VX-inhibited human,
rat, rabbit, and GP AChEs. To further investigate differences
in oxime reactivation between nerve agent-inhibited GP and
human AChEs, we conducted an in Vitro comparative oxime
reactivation study using purified GP and recombinant human
(rHu) AChEs following their inhibition by six different nerve
agents (Figure 1). The second-order reactivation rate con-
stants for five different oximes as well as the aging rate
constants of nerve agent-inhibited AChEs were determined.
Results of this study suggest that, depending on the structures
of nerve agents and oximes, differences in oxime reactivation
between GP and rHu AChE could be very significant. These
results also suggest that guinea pig may not be a suitable
animal model for the evaluation of nerve agent antidotes.
MATERIALS AND METHODS
Purified GP AChE was obtained from 5 L of packed
guinea pig erythrocytes (Harlan, Indianapolis, IN). The
dimeric form of GP AChE was released into solution by
digestion of the anchor that connects the enzyme to
erythrocyte membranes with phosphatidylinositol-specific
phospholipase C (PIPLC; 23). The enzyme was then purified
by affinity chromatography on a procainamide-Sepharose 4B
column (Sigma Chemical Co., St. Louis, MO), followed by
anion-exchange chromatography on DEAE-Sepharose fast
flow column (Amersham Pharmacia, Piscataway, NJ) as
described for the purification of fetal bovine serum AChE
(24). The specific activity of purified GP AChE was 188
units/nmol as determined by titration with DEPQ (25). The
details of the purification procedure will be published
elsewhere. Acetylthiocholine iodide (ATC) and 5,5-dithiobis-
(2-nitrobenzoic acid) (DTNB) were from Sigma Chemical
Co. (St. Louis, MO), and Bio-Spin 6 chromatography
columns were from Bio-Rad (Hercules, CA). Oximes
2-PAM, HI-6, HLo-7, MMB4, and ICD-585 (Figure 1) were
obtained from the Division of Experimental Therapeutics,
Walter Reed Army Institute of Research. The purity of all
oximes was >99% as determined by elemental and HPLC
analyses. Nerve agents GB, GD, GF, GA, VX, and VR were
obtained from the U.S. Army Edgewood Chemical and
Biological Center, Aberdeen Proving Ground, MD. The
purity of all nerve agents was >98.5% as determined by 31P
NMR. Enzyme conjugates with nerve agents GB, GD, GF,
GA, VX, and VR were prepared at U.S. Army Medical
Research Institute of Chemical Defense (USAMRICD).
Recombinant Hu AChE was expressed in a Chinese Hamster
Ovary (CHO) cell line that was stably transfected with a
full-length cDNA for Hu AChE, which was a generous gift
from Dr. Oksana Lockridge (Eppley Institute, University of
Nebraska Medical Center, Omaha, NE). The enzyme purified
by affinity chromatography on procainamide-Sepharose 4B
affinity column had a specific activity of 345 units/nmol.
AChE Assay. AChE activity was determined by the Ellman
method (26). The assay mixture contained 1 mM ATC as
the substrate and 0.5 mM DTNB in 50 mM sodium
phosphate buffer, pH 8.0. The formation of product was
measured at 412 nm at 25 °C.
Determination of Rate Constants for the ReactiVation of
NerVe Agent-Inhibited AChEs by Oximes. Kinetic constants
for the reactivation of nerve agent-inhibited AChEs were
Scheme 1: The Reactions for Aging and Oxime
Reactivation of Nerve Agent-Inhibited AChE as Represented
by AChE-Sarin Conjugate
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determined using a noncontinuous method (27). In order to
minimize the aging of nerve agent-inhibited AChEs, enzyme
conjugates for reactivation studies were prepared in 100 mM
TAPS buffer, pH 9.5. Excess nerve agent was either removed
from AChE-nerve agent conjugate by passing the solution
through a Bio-Spin 6 column or neutralized by adding fresh
enzyme to the solution. AChE-nerve agent conjugates were
stored at -20 °C in 50% glycerol until use. Oxime re-
activation was initiated by making at least a 20-fold dilution
of the AChE-nerve agent conjugate in 50 mM sodium
phosphate buffer, pH 8.0, containing 0.05% bovine serum
albumin (BSA) and different concentrations of oxime. The
solution was maintained at 22 °C, and at specified time
intervals, 5-10 íL of the reactivation mixture was trans-
ferred into a cuvette containing 1-3 mL of assay mixture,
to monitor AChE activity. The final concentration of enzyme
in the assay mixture varied from 0.01 to 0.04 nM. Three
control groups (AChE control, nerve agent-inhibited AChE
control, and AChE with oxime control) were also set up for
the simultaneous monitoring of AChE activity at different
time intervals. Four to six oxime concentrations ranging from
1 íM to 3.2 mM were used for determining the reactivation
rate constants depending on the oxime and OP conjugate.
In order to minimize the possible reinhibition of reactivated
enzyme by phosphoryl oxime (POX) and to ensure an
accurate determination of the reactivation rate constants, the
concentration of AChE-nerve agent conjugate was kept as
low as possible (25). The first-order reactivation rate constant,
kobs, was determined by fitting the experimental data to the
equation for one-phase exponential association:
where t is the time at which the sample was withdrawn; %
(Ereact)t is percent reactivation measured at time t; and A is
percent of maximum reactivation measured after 24 h.
A secondary plot of kobs versus [oxime] was used to obtain
the second-order reactivation rate constant:
where k2 is the intrinsic reaction constant; Kox is the apparent
equilibrium constant; and kr is the second-order reactivation
rate constant.
Since aging (dealkylation) of GD-inhibited AChE is very
fast (half-life of aging is 6 to 20 min under the experimental
conditions), reactivation was always significantly lower than
predicted by the theoretical model if aging was not taken
into account. Therefore, reactivation data were analyzed using
FIGURE 1: Structures of nerve agents and oximes used in the study.
% (Ereact)t ) A(1 - e-kobst) (1)
kobs ) k2/(1 + Kox/[oxime]) (2)
kr ) k2/Kox (3)
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the following equation that accounts for two rates simulta-
neously:
where ka is the aging rate constant for nerve agent-inhibited
AChE. This equation originally was used to calculate the
aging and spontaneous reactivation of GF-inhibited BChE
by Worek et al. (28). Since the spontaneous reactivation of
GD-inhibited AChE is negligible, kobs in this case represents
oxime-induced reactivation. Though the fit was significantly
improved with this equation, deviations between the fit and
the actual data were sometimes still significant. This may
be due to the effect of different oximes on the rate of aging
of GD-inhibited AChE as reported previously (29).
Determination of the Aging Rate Constants of NerVe
Agent-Inhibited AChEs. The aging rate constants of nerve
agent-inhibited AChEs were measured in 50 mM sodium
phosphate buffer, pH 8.0, at 37 °C. AChE-nerve agent
conjugates prepared in 100 mM TAPS buffer, pH 9.5, were
diluted at least 20-fold with 50 mM sodium phosphate buffer,
pH 8.0, containing 0.1% BSA. Aliquots of enzyme (10 íL)
were withdrawn at different time intervals, and transferred
to tubes containing 0.2-1 mM oxime. TMB4 was used for
GA-inhibited GP and rHu AChEs, while HLo-7 was used
for all other AChE-nerve agent conjugates. The samples
were assayed for AChE activity after incubation for 5 h to
ensure the maximum reactivation of the nerve agent-inhibited
AChE. The aging rate constant (ka) of nerve agent-inhibited
AChE was calculated according to the following equation
for first-order decay:
where A is the maximum percent reactivation of AChE
activity after incubation with oxime and t is the time at which
aliquots of enzyme were withdrawn.
RESULTS
ReactiVation of G Agent-Inhibited GP and Hu AChEs by
Oximes. GP and rHu AChEs were inhibited by four different
G-type nerve agents, and reactivation kinetic studies were
conducted with five different mono- and bis-pyridinium
oximes. Examples of reactivation kinetics are shown in
Figures 2A and 2B. In Figure 2B, where the secondary plot
followed a saturation curve, the second-order reactivation
rate constant (kr) was obtained from the ratio of k2/Kox. In
cases where a linear correlation was observed instead of the
saturation curve as shown in Figure 3B, k2 and Kox could
not be determined and kr was estimated from the slope of
the line. As mentioned above, only partial reactivations of
GD-inhibited GP and rHu AChEs were achieved due to their
fast aging, and kobs were obtained by fitting the experimental
data to eq 4 to accommodate the effect of aging (Figures
4A and 4B). Kinetic rate constants (k2, Kox, kr) for the
reactivation of different G agent-inhibited GP and rHu
AChEs are summarized in Tables 1-4. Results show that
except for GA-inhibited GP and rHu AChEs which could
not be reactivated by HI-6 and ICD-585, the reactivation
rates of rHu AChE inhibited by all four G agents were faster
than those for GP AChE. However, differences in the second-
order reactivation constants between these two enzymes
depend both on the oxime and on the nerve agent used and
vary from a little over 1-fold to 435-fold. Smaller apparent
equilibrium constants (Kox) coupled with faster intrinsic
reaction constants (k2) were generally observed for the
reactivation of rHu AChE-nerve agent by the four bis-
pyridinium oximes. These differences were generally more
FIGURE 2: Reactivation kinetics of GB-inhibited rHu AChE by 2-PAM. Panel A: Reactivation kinetics of GB-inhibited rHu AChE by four
different concentrations of 2-PAM (0.1 to 0.8 mM). Panel B: Secondary plot of the kobs vs [2-PAM] for the calculation of reactivation rate
constants.
FIGURE 3: Reactivation kinetics of GF-inhibited rHu AChE by MMB4. Panel A: Reactivation kinetics of GF-inhibited rHu AChE by four
different concentrations of MMB4 (0.005 to 0.04 mM). Panel B: Secondary plot of the kobs vs [MMB4] for the calculation of second-order
reactivation rate constant.
% (Ereact)t ) kobsA/(kobs + ka)(1 - e-(kobs+ka)t) (4)
% (Ereact)t ) A e-kat (5)
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pronounced for the reactivation of GD- and GF-inhibited
enzymes by HI-6, HLo-7, and ICD-585. Differences in the
second-order reactivation rate constants between these two
enzymes were much smaller with the mono-pyridinium
oxime 2-PAM, with krs for GB-, GD-, and GF-inhibited rHu
AChE being only 1.2- to 3-fold faster than GP AChE. The
enzyme conjugates with GA were more resistant to reactiva-
tion by oximes compared to other conjugates, and no
noticeable reactivation was observed with HI-6 or ICD-585.
The kr of GA-inhibited rHu AChE was 2- to 15-fold higher
than that for GP AChE with 2-PAM, MMB4, and HLo-7.
The best oxime for GA-inhibited AChE was HLo-7, with a
kr of 62 M-1 min-1.
ReactiVation of V Agent-Inhibited GP and Hu AChEs by
Oximes. Oxime reactivation studies were also conducted with
GP and rHu AChEs inhibited by V-type nerve agents VX
and VR. Since the stereoselectivity of VX is significantly
less for the inhibition of AChE than with other nerve agents
such as GB and GD (30-32), both enantiomers of VX inhibit
AChE, yielding two different AChE-OP conjugates that are
reactivated at different rates by oxime (33). Also, AChE-
VX conjugates corresponding to the two enantiomers were
not at a 1:1 ratio; therefore, a mathematical solution to obtain
individual reactivation rate constants for each species in the
mixture was difficult. The experimental data were fitted using
a one-phase exponential association model to calculate an
FIGURE 4: Reactivation kinetics of GD-inhibited GP AChE by MMB4. Panel A: Reactivation kinetics of GD-inhibited GP AChE by four
different concentrations of MMB4 (0.1 to 0.8 mM); data were fit to eq 4 for the calculation of kobs for each oxime concentration. Panel B:
Secondary plot of kobs vs [MMB4] for the calculation of second-order reactivation rate constant.
Table 1: Rate Constantsa for the Reactivation of GB-Inhibited GP and Hu AChEs by Different Oximes
GP AChE rHu AChE
oxime
k2
(min-1)
Kox
(mM)
kr
(mM-1 min-1)
k2
(min-1)
Kox
(mM)
kr
(mM-1 min-1)
2-PAM 0.070 ( 0.022 0.342 ( 0.126 0.206 0.123 ( 0.032 0.266 ( 0.150 0.462
MMB4 0.076 ( 0.005 0.294 ( 0.031 0.257 ndb ndb 0.770
HI-6 0.020 ( 0.007 0.067 ( 0.012 0.297 0.128 ( 0.011 0.022 ( 0.010 5.953
HLo-7 0.070 ( 0.009 0.100 ( 0.029 0.696 0.320 ( 0.046 0.028 ( 0.010 11.430
ICD-585 0.039 ( 0.021 0.147 ( 0.045 0.267 0.157 ( 0.066 0.072 ( 0.030 2.160
a Data are means ( standard errors from 2-4 determinations. b Value could not be determined due to the linear relationship of kobs vs [oxime].
Table 2: Rate Constantsa for the Reactivation of GD-Inhibited GP and Hu AChEs by Different Oximes
GP AChE rHu AChE
oxime
k2
(min-1)
Kox
(mM)
kr
(mM-1 min-1)
k2
(min-1)
Kox
(mM)
kr
(mM-1 min-1)
2-PAM 0.029 ( 0.009 1.730 ( 0.24 0.017 0.262 ( 0.113 5.090 ( 1.590 0.052
MMB4 0.064 ( 0.020 2.310 ( 0.520 0.038 ndb ndb 0.785
HI-6 0.026 ( 0.013 0.910 ( 0.310 0.051 0.183 ( 0.040 0.009 ( 0.004 21.510
HLo-7 0.067 ( 0.026 0.490 ( 0.170 0.140 0.307 ( 0.080 0.012 ( 0.006 26.180
ICD-585 0.015 ( 0.004 1.310 ( 0.480 0.012 0.432 ( 0.161 0.170 ( 0.048 2.540
a Due to the rapid aging of GD-inhibited GP and Hu AChEs, reactivation by oximes was immediately started after inhibition of AChE by GD
in pH 9.5 buffer, and kobs at each oxime concentration was obtained by fitting the data to eq 4. Data are means ( standard errors from 2-4
determinations. b Value could not be determined due to the linear relationship of kobs vs [oxime].
Table 3: Rate Constantsa for the Reactivation of GF-Inhibited GP and Hu AChEs by Different Oximes
GP AChE rHu AChE
oxime
k2
(min-1)
Kox
(mM)
kr
(mM-1 min-1)
k2
(min-1)
Kox
(mM)
kr
(mM-1 min-1)
2-PAM 0.016 ( 0.004 2.234 ( 0.380 0.007 0.035 ( 0.012 1.247 ( 0.650 0.028
MMB4 0.277 ( 0.062 1.981 ( 0.434 0.140 ndb ndb 5.100
HI-6 0.067 ( 0.054 0.506 ( 0.323 0.133 1.040 ( 0.240 0.035 ( 0.016 29.700
HLo-7 0.076 ( 0.029 0.383 ( 0.288 0.139 1.620 ( 0.453 0.019 ( 0.006 85.060
ICD-585 0.039 ( 0.021 0.226 ( 0.053 0.174 0.320 ( 0.070 0.020 ( 0.040 15.790
a Data are means ( standard errors from 2-4 determinations. b Value could not be determined due to the linear relationship of kobs vs [oxime].
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average rate constant for the reactivation of VX-inhibited
AChE. Rate constants for the reactivation of VX- and VR-
inhibited GP and rHu AChEs by different oximes are
summarized in Tables 5 and 6, respectively. Results showed
that with VR-inhibited AChEs, differences between GP and
rHu AChEs were similar to those observed with GF, GD,
and GB. The second-order reactivation rate constants by these
five oximes were 12- to 211-fold faster for rHu AChE than
GP AChE, which were due to both faster k2 and lower
binding affinity (higher Kox). But the differences were smaller
with VX-inhibited enzymes. The most significant difference
was observed with HLo-7, where kr was 15-fold faster for
VX-inhibited rHu AChE than that for GP AChE. With the
mono-pyridinium oxime 2-PAM, the reactivation of VX-
inhibited rHu AChE was a little slower than that of GP
AChE. In most cases, the faster kr values of VX-inhibited
rHu AChE were mainly due to the higher binding affinity
of oximes for rHu AChE conjugates than for GP AChE
conjugates.
A comparison of kr values for oxime reactivation of nerve
agent-inhibited GP and rHu AChEs is shown in Figure 5.
By assigning a value of 1 to the kr for GP AChE, each bar
in Figure 5 represents the relative potency of an oxime for
the reactivation of rHu AChE inhibited by the nerve agent
compared to that for GP AChE. Data shows that the oxime
reactivation of nerve agent-inhibited rHu AChE was gener-
ally faster than that of GP AChE. The most pronounced
differences were observed when GF-, GD-, and VR-inhibited
AChEs when reactivated by HLo-7, HI-6, and ICD-585, with
kr values that were 90- to 435-fold higher. Differences of
less than 20-fold were observed in the oxime reactivation
of two enzymes inhibited with other nerve agents, except
for the reactivation of GF-inhibited AChEs by MMB4 and
GB-inhibited AChEs by HLo-7, where up to 30-fold differ-
ences were observed.
Aging Rate Constants of NerVe Agent-Inhibited GP and
Hu AChEs. The aging of GP and rHu AChEs inhibited by
six different nerve agents was examined by determining the
maximum reactivation obtained after incubation of the
Table 4: Rate Constantsa for the Reactivation of GA-inhibited GP and Hu AChEs by Different Oximes
GP AChE rHu AChE
oxime
k2
(min-1)
Kox
(mM)
kr
(mM-1 min-1)
k2
(min-1)
Kox
(mM)
kr
(mM-1 min-1)
2-PAM 0.002 ( 0.001 1.210 ( 0.340 0.002 0.008 ( 0.006 1.320 ( 0.770 0.006
MMB4 0.006 ( 0.001 10.580 ( 2.450 0.001 0.013 ( 0.008 2.990 ( 1.230 0.004
HI-6 ndb ndb ndb ndb ndb ndb
HLo-7 0.003 ( 0.002 0.720 ( 0.410 0.004 0.005 ( 0.001 0.080 ( 0.004 0.062
ICD-585 ndb ndb ndb ndb ndb ndb
a Data are means ( standard errors from 2-4 determinations. b Reactivation was so insignificant that the reactivation kinetic constants could not
be calculated.
Table 5: Rate Constantsa for the Reactivation of VX-Inhibited GP and Hu AChEs by Different Oximes
GP AChE rHu AChE
oxime
k2
(min-1)
Kox
(mM)
kr
(mM-1 min-1)
k2
(min-1)
Kox
(mM)
kr
(mM-1 min-1)
2-PAM 0.012 ( 0.001 0.074 ( 0.005 0.160 0.031 ( 0.013 0.272 ( 0.121 0.117
MMB4 0.184 ( 0.072 2.238 ( 1.475 0.082 0.024 ( 0.008 0.137 ( 0.060 0.177
HI-6 0.004 ( 0.001 0.057 ( 0.002 0.074 0.014 ( 0.005 0.014 ( 0.008 1.045
HLo-7 0.024 ( 0.004 0.088 ( 0.006 0.267 0.018 ( 0.007 0.004 ( 0.001 4.230
ICD-585 0.007 ( 0.001 0.059 ( 0.021 0.124 0.013 ( 0.005 0.018 ( 0.007 0.670
a Data are means ( standard errors from 2-4 determinations.
Table 6: Rate Constantsa for the Reactivation of VR-Inhibited GP and Hu AChEs by Different Oximes
GP AChE rHu AChE
oxime
k2
(min-1)
Kox
(mM)
kr
(mM-1 min-1)
k2
(min-1)
Kox
(mM)
kr
(mM-1 min-1)
2-PAM 0.016 ( 0.007 2.230 ( 0.320 0.017 0.080 ( 0.030 0.317 ( 0.112 0.252
MMB4 0.277 ( 0.043 1.980 ( 0.262 0.140 ndb ndb 1.760
HI-6 0.134 ( 0.027 0.166 ( 0.041 0.081 0.225 ( 0.033 0.012 ( 0.002 19.580
HLo-7 0.066 ( 0.016 0.272 ( 0.132 0.243 0.582 ( 0.340 0.013 ( 0.004 43.80
ICD-585 0.015 ( 0.068 0.184 ( 0.030 0.082 0.872 ( 0.280 0.051 ( 0.018 16.760
a Data are means ( standard errors from 2-4 determinations. b Values could not be determined due to the linear relationship of kobs vs [oxime].
FIGURE 5: The ratios of the second-order oxime reactivation rate
constants of nerve agent-inhibited rHu AChE and GP AChE for
different oximes. The bars in the graph represent the ratios of kr
values between reactivation of nerve agent-inhibited rHu AChE
and GP AChE by the same oxime.
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AChE-OP conjugates in 50 mM phosphate buffer, pH 8.0,
containing an oxime, at 37 °C. In each case, the most
effective oxime was used. The aging rate constants and the
half-times of aging are summarized in Table 7. Results
showed that the most significant difference in aging was
observed with GD-inhibited AChEs, since GD-inhibited rHu
AChE aged 3 times faster than GP AChE. The aging of GF-
inhibited rHu AChE was also 70% faster than that of GP
AChE. For AChEs inhibited by GB, GA, and VX, there were
no significant differences between these two enzymes. The
aging of VR-inhibited rHu AChE could not determined due
to the relatively poor stability of rHu AChE at 37 °C and
the fast spontaneous reactivation of VR-AChE conjugate.
However, the half-time of aging of 325 h for VR-inhibited
GP AChE suggests that the aging of rHu AChE-VR
conjugate should not significantly affect oxime reactivation.
DISCUSSION
AChE is one of the most efficient enzymes, with a turnover
number of over 10-4 s-1 (34). This high catalytic efficiency
is maintained in AChEs across animal species as indicated
by the high homology in the amino acid sequences of these
enzymes. Despite this high homology, many studies have
revealed significant species-related differences between these
enzymes with regard to interaction with inhibitors (35-39).
On the other hand, most oxime reactivation studies with
enzyme-OP conjugates from different AChEs only indicated
moderate species-related variations in reactivation rates (27,
40, 41), with the exception of HI-6, which showed that the
reactivation of GD-inhibited eel AChE was remarkably
slower than that of Hu AChE (42, 43). More recently, notable
species-related differences between the reactivation of GP
and Hu AChE were reported when guinea pig or pig and
human erythrocyte ghost cell AChEs were compared (22,
44). Since guinea pig is a frequently used animal model for
evaluating oxime therapy, these results indicate that species-
related differences in oxime reactivation between GP and
Hu AChE may be problematic in extrapolating experimental
animal data to humans. Therefore, in this study, we con-
ducted a complete characterization of the aging and reactiva-
tion properties of purified GP and rHu AChEs. This
comprehensive reactivation study using six classical OP
nerve agents and five different oximes revealed novel and
interesting differences between the oxime reactivation of
nerve agent-inhibited GP and rHu AChEs. In general, the
reactivation of rHu AChE inhibited by different G- and
V-type nerve agents by these oximes was faster than GP
AChE. The most pronounced species-related differences were
observed in the reactivation of GF-, GD-, and VR-inhibited
AChEs by HLo-7, HI-6, and ICD-585. In these cases, the
second-order reactivation rate constants of rHu AChE were
90- to 435-fold higher than those for GP AChE. With the
mono-pyridinium oxime 2-PAM, the differences between
these two AChEs were much smaller, and in some cases the
reactivation was faster for GP AChE. These results strongly
suggest that the guinea pig may be not a suitable animal
model for the in ViVo screening of oximes for the develop-
ment of antidotes for humans, since the use of equal molar
doses in this animal model may lead to an assessment of
oxime efficacies which is not appropriate for humans.
Similarly, some potential oximes that are suitable for humans
may be dismissed based upon their poor efficacy in guinea
pigs.
For the reactivation of all six enzyme-nerve agent
conjugates by most of the tested oximes, the plot of kobs vs
[oxime] followed a saturation curve, which allowed the
determination of both the Kox and k2 as shown in Tables 1
to 6. However, kinetics for MMB4 reactivation of rHu
AChEs inhibited by four of the six nerve agents displayed a
linear relationship between kobs and [MMB4]. Under these
conditions, the association of MMB4 with the enzyme-OP
conjugate may be the rate-limiting step in the reactivation
reaction. If higher concentrations of MMB4 were used,
saturation in the binding of MMB4 to the AChE-OP
conjugate would be achieved. However, due to practical
reasons, it was not possible to conduct reactivation studies
with higher concentrations of MMB4.
Reactivation rate constants for GB- and GF-inhibited
AChEs determined using purified enzymes in this study were
comparable to those reported previously with erythrocyte
ghosts (22). However, significantly higher second-order
reactivation rate constants were observed for VX-inhibited
GP and Hu AChEs in the previous study than those reported
here. The reason for this discrepancy may be that reactivation
kinetics were only measured over the first 10 min in the last
study, while in the present study, the course of reactivation
was measured for up to 2 h. Since VX can form two AChE-
VX conjugates corresponding to the two enantiomers, which
undergo oxime reactivation at different rates, the monitoring
of reactivation for the first 10 min may mostly represent
reactivation of the conjugate that reactivates faster. This
discrepancy can be resolved by conducting reactivation
studies with separate enzyme conjugates prepared from each
of the two enantiomers of VX.
Differences in the rates of aging of nerve agent-inhibited
GP and rHu AChEs were significantly less than those
observed for oxime reactivation rates, with the most signifi-
cant difference being 3-fold between GD-inhibited GP and
rHu AChEs. Although the rate of aging was very low for
GA-inhibited GP and rHu AChEs, these conjugates were
much more difficult to reactivate compared with enzyme
conjugates with other nerve agents. Only three of five tested
Table 7: Aging Rate Constantsa (ka) for Nerve Agent-Inhibited GP and rHu AChEs
ka, h-1  10-2
enzyme GB GD GF GA VX VR
GP AChE 5.33 ( 0.64 167.61 ( 43.25 0.91 ( 0.06 0.94 ( 0.07 0.18 ( 00.04 0.21 ( 0.02
(13) (0.42) (76) (73) (380) (325)
rHu AChE 6.45 ( 0.67 677.64 ( 103.62 1.69 ( 0.17 0.70 ( 0.08 0.19 ( 0.05 ndb
(11) (0.1) (41) (99) (357)
a Values of kas and the least-squares errors were determined in 50 mM sodium phosphate buffer, pH 8.0, at 37 °C; values in parentheses are
half-times for aging in hours. b ND, not determined.
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oximes (2-PAM, MMB4, and HLo-7) were able to induce
measurable reactivations of GA conjugate. The two other
oximes (HI-6 and ICD-585) failed to reactivate either GP
or rHu AChE inhibited by GA, providing further proof for
the resistance of enzyme-GA conjugate to oxime reactiva-
tion. The recent X-ray crystal structure of mouse AChE-
GA conjugate revealed that there was a repositioning of
amino acid residues in GA-inhibited AChE compared with
other enzyme conjugates (45). Also, the X-ray crystal
structure of mouse AChE-HI-6 complex showed that the
secondary pyridinium ring of HI-6 was sandwiched between
W286 and Y124 of the peripheral anionic site (PAS) of
AChE (10). These unique features may explain the unsuc-
cessful reactivation of AChE-GA conjugates by HI-6 and
ICD-585 observed in this study.
The most interesting observations were the pronounced
differences in the reactivation of GF-, GD-, and VR-inhibited
GP and rHu AChEs by HLo-7, HI-6, and ICD-585. In the
1980s, the H-series oximes HI-6 and HLo-7 were reported
to be potent reactivators of AChE inhibited by GD, a nerve
agent with a bulky pinacolyl side chain (46). Subsequent
studies reported that these oximes were also potent reacti-
vators of AChE inhibited by GF, another nerve agent with
a bulky side chain (cyclohexyl) (28). The iso-butyryl side
chain of VR is also relatively bulkier than other nerve agents
such as VX and GB. Therefore, the high potencies of these
three oximes in reactivating GF-, GD-, and VR-inhibited rHu
AChE may stem from a unique interaction of these oximes
with Hu AChE to overcome the steric hindrance from these
bulky side chains. Site-directed mutagenesis studies have
indicated that reactivation by HI-6 and HLo-7 depends on
the interaction of the second-pyridinium structure of oxime
with the PAS of AChE (32, 47). It is possible that there may
be differences in amino acid residues at the PAS of GP and
Hu AChE which may be responsible for species-related
variations observed in oxime reactivation between these two
enzymes. The determination of amino acid sequence for GP
AChE and its comparison with Hu AChE are necessary for
explaining differences between these enzymes regarding
oxime reactivation following nerve agent inhibition.
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